Back to search

Article

Hidden-driver inference reveals synergistic brain-penetrant therapies for medulloblastoma

2026-03-06

Abstract excerpt

<title>Abstract</title> <p>Effective therapies for high-risk medulloblastoma (MB), particularly MYC-driven Group 3 (G3) MB, remain elusive due to limited druggable mutations, poor blood–brain barrier (BBB) penetration, and rapid resistance. We developed SINBA (Synergy Inference by Data-driven Network-Based Bayesian Analysis), a systems biology framework that predicts synergistic, BBB-permeable drug combinations b...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
caa6e05e-7938-5ae7-af16-b5ac7eb4c92c
DOI
10.21203/rs.3.rs-8278592/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Hidden-driver inference reveals synergistic brain-penetrant therapies for medulloblastomaDOI 10.21203/rs.3.rs-8278592/v1
Hidden-driver inference reveals synergistic brain-penetrant therapies for medulloblastomaSemantic proximity
Functional genomics identifies therapeutic options, biomarkers, and resistance mechanisms for high-grade gliomasSemantic proximity
Elucidation and Pharmacologic Targeting of Master Regulator Dependencies in Coexisting Diffuse Midline Glioma SubpopulationsSemantic proximity
Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastomaSemantic proximity
Integrative omics data analysis uncovers biomarker genes and potential candidate drugs for G3 medulloblastomaSemantic proximity
DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets.Semantic proximity
Long-term outcomes by clinical and molecular risk stratification in patients with medulloblastoma receiving risk-adapted therapy.Semantic proximity
Differential gene expression-based connectivity mapping identified novel drug candidate and improved Temozolomide efficacy for GlioblastomaSemantic proximity
Patient-Derived Orthotopic Xenografts and Cell Lines from Pediatric High-Grade Glioma Recapitulate the Heterogeneity of Histopathology, Molecular Signatures, and Drug ResponseSemantic proximity
Integrating genomic, transcriptomic and epigenetic data to identify phenotypically impactful driver pathways in glioblastomaSemantic proximity
In silico drug sensitivity predicts subgroup-specific therapeutics in medulloblastoma patientsSemantic proximity
Integrative Multiomics and Drug Sensitivity Profiling Reveal Potential Biomarkers and Therapeutic Strategies in Pediatric Solid Tumors.Semantic proximity
Select a neighboring publication to make it the new centre.